
The Lancet Gastroenterology & Hepatology
Fecha de publicación: 2 de febrero de 2021
DOI: https://doi.org/10.1016/S2468-1253(21)00016-9
Autores: Prof Shaji Sebastian, MD *, Gareth J Walker, PhD *, Nicholas A Kennedy, PhD *, Thomas E Conley, MBChB, Kamal V Patel, MRCP, Sreedhar Subramanian, MD, Alexandra J Kent, MRCP, Jonathan P Segal, PhD, Prof Matthew J Brookes, PhD, Neeraj Bhala, DPhil, Haidee A Gonzalez, MBBS, Lucy C Hicks, PhD, Shameer J Mehta, MD(Res), Christopher A Lamb, PhD
Background: There is a paucity of evidence to support safe and effective management of patients with acute severe ulcerative colitis during the COVID-19 pandemic. We sought to identify alterations to established conventional evidence-based management of acute severe ulcerative colitis during the early COVID-19 pandemic, the effect on outcomes, and any associations with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe COVID-19 outcomes.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.